Antag Therapeutics is advancing its first-in-class GIP receptor antagonist AT7687, with new data to be showcased at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. The company will deliver both an oral and a poster presentation, underscoring growing clinical and scientific momentum in obesity and metabolic disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chief Medical Officer Richard Nkulikiyinka will present first-in-human results from AT7687 in healthy volunteers and individuals with obesity, with data indicating the drug is well tolerated and suitable for once-weekly subcutaneous dosing. These findings highlight a potentially differentiated mechanism in the crowded obesity pipeline.
Chief Scientific Officer Mads Tang-Christensen will present preclinical data on combining AT7687 with cagrilintide, a dual amylin and calcitonin receptor agonist known for weight-loss efficacy. In obese, insulin-resistant non-human primates, the combination produced marked weight reduction along with substantial gains in insulin sensitivity and body composition.
The company is preparing a Phase 2a obesity program for mid-2026, building on a recently completed Phase 1 trial. Antag Therapeutics is backed by an €80 million Series A round led by specialist life sciences investors and grounded in decades of metabolic research associated with GLP-1 pioneer Professor Jens Juul Holst.
For investors, the ADA presentations provide important early validation of AT7687’s safety, pharmacology, and combination potential with established incretin-based agents. This increased scientific visibility may support Antag Therapeutics’ efforts to secure partnerships and additional funding as it positions itself in the next wave of obesity therapeutics.
Overall, the week’s developments highlight a period of strategic progress for Antag Therapeutics, with upcoming data disclosures expected to shape perceptions of its pipeline’s competitive profile and long-term commercial prospects in obesity and metabolic disease.